EVP and Chief Commercial Officer Bryan Downey explains Indegene’s role in Cingulate’s commercialization efforts for CTx-1301 in ADHD. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #ControlledRelease #Dexmethylphenidate
youtube.com/shorts/UnnYM...

As we advance to CTx-1301’s 31May26 target action date, Cingulate SVP of Market Access Rick Arce explains the process of getting payors on board. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #Dexmethylphenidate
youtube.com/shorts/T-fYV...